Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Memorial Sloan Kettering Cancer Center
Modality
radiopharmaceutical
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02307630CT.gov PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Sarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 124i-humanized 3f8 (this asset) | Memorial Sloan Kettering Cancer Center | N/A | D · 30 |
| Etoposide | National Cancer Institute (NCI) | P2 | BB |
| Cyclophosphamide | Essen Biotech | P2 | BB |
| Isocyclophosphamide | City of Hope Medical Center | P3 | BB |
| Carboplatin | OHSU Knight Cancer Institute | P2 | BB |
| Adriamycin | City of Hope Medical Center | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Roswell Park Cancer Institute | P2 | BB |
| Nivestim | Masonic Cancer Center, University of Minnesota | P3 | BB |
| Sodium Thiosulfate | Mayo Clinic | P3 | BB |
+42 more in the Sarcoma cohort
Other indications for 124i-humanized 3f8
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neuroblastoma | — | N/A | D · 30 |
| Melanoma | — | N/A | D · 28 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 124i-humanized 3f8 in Sarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/124i-humanized-3f8-sarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →